Protective anti-glucan antibodies with preference for beta-1,3- glucans
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorsAntonio Cassone, Antonella Torosantucci
Life of this patent
Estimating the term…
Abstract
Anti-β-1,3-glucan antibodies have been found to be protective against systemic fungal infection with Candida albicans. The present invention provides monoclonal antibodies that bind to β-1,3-glucan, hybridoma cell lines producing the antibodies, compositions comprising the antibodies and methods of using such antibodies for treatment of microbial infections, particularly against Candida albicans and Aspergillus fumigatis infections. The antibodies of the present invention are not specific for β-1,6-glucan.
Claims21
A monoclonal antibody that can protect a mammal against infection by a microbial pathogen, wherein the pathogen has a cell wall containing β-1,3-glucan and β-1,6-glucan, and wherein the monoclonal antibody shows preferential binding to the β-1,3-glucan over the β-1,6-glucan.
(canceled)
(canceled)
Dependencies are inferred from the claim text.